Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates

• Published in: Archives of disease in childhood 2022-01, Vol.107 (1), p.86-91
• Main Authors: Samiee-Zafarghandy, Samira, van Donge, Tamara, Fusch, Gerhard, Pfister, Marc, Jacob, George, Atkinson, Andrew, Rieder, Michael J, Smit, Cornelis, Van Den Anker, John
• Format: Article
• Language: English
• Subjects: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics; Area Under Curve; Birth weight; Body Weight; Congenital diseases; Coronary vessels; Creatinine; Dosage; Drug dosages; Drug Monitoring - methods; Drug therapy; Ductus Arteriosus, Patent - drug therapy; Female; Gestational Age; Humans; Ibuprofen; Ibuprofen - administration & dosage; Ibuprofen - pharmacokinetics; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases - drug therapy; Infant, Very Low Birth Weight; Intensive Care Units, Neonatal; Laboratories; Male; Meta Analysis; Neonates; neonatology; Newborn babies; Nonsteroidal anti-inflammatory drugs; Pediatrics; Pharmacokinetics; pharmacology; Plasma; Population; Premature babies; Premature Infants; Prospective Studies; Sampling; Scientific Concepts; Success; Therapeutic drug monitoring; Urine; Young Children
• ISSN: 0003-9888; 1468-2044
• DOI: 10.1136/archdischild-2020-321381

ObjectiveExploration of a novel therapeutic drug monitoring (TDM) strategy to personalise use of ibuprofen for closure of patent ductus arteriosus (PDA) in preterm neonates.DesignProspective, single-centre, open-label, pharmacokinetics study in preterm neonates.SettingNeonatal intensive care unit at McMaster Children’s Hospital.PatientsNeonates with a gestational age ≤28+6 weeks treated with oral ibuprofen for closure of a PDA.MethodsPopulation pharmacokinetic parameters, concentration-time profiles and exposure metrics were obtained using pharmacometric modelling and simulation.Main outcome measureAssociation between ibuprofen plasma concentrations measured at various sampling time points on the first day of treatment and attainment of the target exposure over the first 3 days of treatment (AUC0–72h >900 mg·hour/L).ResultsTwenty-three preterm neonates (median birth weight 780 g and gestational age 25.9 weeks) were included, yielding 155 plasma ibuprofen plasma samples. Starting from 8 hours’ postdose on the first day, a strong correlation between ibuprofen concentrations and AUC0–72h was observed. At 8 hours after the first dose, an ibuprofen concentration >20.5 mg/L was associated with a 90% probability of reaching the target exposure.ConclusionWe designed a novel and practical TDM strategy and have shown that the chance of reaching the target exposure (AUC0–72h >900 mg·hour/L) can be predicted with a single sample collection on the first day of treatment. This newly acquired knowledge can be leveraged to personalise ibuprofen dosing regimens and improve the efficacy of ibuprofen use for pharmacological closure of a PDA.